


MeRes-1 Extend Study


Study Highlights

- Principal Investigator: Dr. Alexandre Abizaid
- The MeRes-1 Extend was a prospective, multicenter, single-arm, trial of MeRes100 sirolimus-eluting bioresorbable vascular scaffold system in patients with de novo native coronary artery lesions
- Three-year clinical follow-up including
 - QCA analysis at 6 and 36 months
 - OCT analysis at 6 and 36 months
- MeRes-1 Extend study demonstrated the favourable safety and efficacy of MeRes100 BRS at 24 months follow-up



❖ Study Design

A multicentre, single-arm, prospective study




A total of 64 patients were enrolled in Spain, FYR of Macedonia, Brazil, South Africa, Malaysia and Indonesia



Clinical follow-up at 1 month, 6 months, 12 months, 24 months and 36 months post-procedure



Angiographic follow-up at 6 and 36 months
Analysed by Cardiovascular Research Centre, Sao Paulo, Brazil



OCT follow-up at 6 and 36 months
Analysed by Cardialysis BV, Rotterdam, the Netherlands

❖ Clinical Presentation




Figure 1: Cardiac Status




Figure 2: Lesion Characteristics (ACC/AHA Classification)

❖ Study Results




Figure 3: Late lumen loss at 6-month follow-up

❖ References

1. ClinicalTrial.gov no: NCT02663323
<https://clinicaltrials.gov/ct2/show/NCT02663323>
2. Presented by Alexandre Abizaid. Evidences from the meriT-V randomized trial on BioMime SES and from MeRes-1 Extend, MeRes100 BRS 1st in man evaluation. At EUROPCR 2017.
<https://www.pcronline.com/Cases-resources-images/Resources/Educational-interviews/Evidences-from-the-meriT-V-randomized-trial-on-BioMime-SES-and-from-MeRes-1-Extend-MeRes100-BRS-1st-in-man-evaluation>
3. Presented by Alexandre Abizaid. MeRes-1 Extend: One-Year Clinical Results with a Thin-Strut PLLA Based Sirolimus-Eluting BRS in Patients with Coronary Artery Disease. At EUROPCR 2018.
<http://www.crtonline.org/presentation-detail/meres-1-extend-one-year-clinical-results-with-thin>
4. Presented by Praveen Chandra. Next generation BRS-MeRes100 science & clinical update. TCT-2018.
5. Presented by Alexandre Abizaid. Implantation of Thin Strut Sirolimus-Eluting Bioresorbable Vascular Scaffold in Patients With de novo Coronary Artery Lesions: Two-year Clinical and Six-month Imaging Outcomes of the MeRes-1 Extend Trial. Accepted in abstract book of Euro Intervention 2019.
6. Presented by Alexandre Abizaid. Clinical and imaging outcomes of thin-strut sirolimus-eluting BRS in patients with de novo coronary artery lesions: the MeRes-1 Extend trial. Accepted in abstract book of Euro Intervention 2020.